Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1526 - 1550 of 2306 in total
BMS-908662 has been used in trials studying the treatment of Melanoma and Colorectal Cancer.
Investigational
BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer.
Investigational
Matched Iupac: … (2R,3S)-N-[(3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3 …
BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
Investigational
BMS-986142 is under investigation in clinical trial NCT02880670 (Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects).
Investigational
GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237...
Investigational
Matched Iupac: … pyridazin-3-yl}methyl)amino]piperidin-1-yl}methyl)-5-fluoro-1-azatricyclo[6.3.1.0^{4,12}]dodeca-4,6,8(12),9- …
Investigational
CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
Investigational
Yttrium Y-90 clivatuzumab tetraxetan is under investigation in clinical trial NCT00603863 (Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer).
Investigational
Experimental
Matched Iupac: … (2R,6S,7R)-7-(4-hydroxyphenyl)-10-(methoxymethyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien …
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
Matched Mixtures name: … HydroGold 9
Investigational
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
Investigational
Investigational
Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
Investigational
Experimental
Matched Iupac: … (2S)-1-(3,6-dibromo-9H-carbazol-9-yl)-3-(dimethylamino)propan-2-ol …
Experimental
Matched Iupac: … (2R,6S,7R)-4,4-difluoro-7-(4-hydroxyphenyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien-12-ol …
Argireline has been used in trials studying the treatment of wrinkles.
Investigational
Matched Mixtures name: … HydroGold 9
Experimental
AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Investigational
Investigational
DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1). DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy).
Investigational
BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.
Investigational
AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.
Investigational
KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased potency, favorable tissue distribution, and ease of formulation.
Investigational
Displaying drugs 1526 - 1550 of 2306 in total